NovoCure (NVCR) EBIT Margin (2014 - 2026)
NovoCure recorded quarterly EBIT Margin of 38.73% in Q1 2026, down 67.19% quarter-over-quarter from 23.17% in Q4 2025, and down 1430.0% year-over-year from 2.91% in Q1 2025.
NovoCure's EBIT Margin history runs 13 years deep, the most recent figure standing at 38.73% for Q1 2026.
- In Q1 2026, EBIT Margin fell 1430.0% year-over-year to 38.73%; the TTM figure through Mar 2026 stood at 27.19% (down 35.0% YoY), while the FY2025 annual figure was 23.47%, up 470.0% from the prior year.
- EBIT Margin came in at 38.73% for Q1 2026 at NovoCure, down from 23.17% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 0.59% in Q1 2022 to a low of 49.71% in Q2 2023.
- A 5-year average of 29.19% and a median of 24.89% in 2025 frame the typical range for EBIT Margin.
- Across the five-year window, EBIT Margin tumbled 4872 bps in 2023 and soared 2738 bps in 2024, its largest moves.
- NovoCure's EBIT Margin stood at 33.46% in 2022, then retreated by 16 bps to 38.66% in 2023, then fell by 2 bps to 39.25% in 2024, then surged by 41 bps to 23.17% in 2025, then slumped by 67 bps to 38.73% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 38.73%, 23.17%, and 21.54% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 16.24% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 28.97% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 6.17% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 21.42% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 10.04% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 19.94% |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn | -38.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.73% |
| Dec 31, 2025 | -23.17% |
| Sep 30, 2025 | -21.54% |
| Jun 30, 2025 | -24.89% |
| Mar 31, 2025 | -24.43% |
| Dec 31, 2024 | -39.25% |
| Sep 30, 2024 | -20.69% |
| Jun 30, 2024 | -22.33% |
| Mar 31, 2024 | -29.98% |
| Dec 31, 2023 | -38.66% |
| Sep 30, 2023 | -45.75% |
| Jun 30, 2023 | -49.71% |
| Mar 31, 2023 | -49.31% |
| Dec 31, 2022 | -33.46% |
| Sep 30, 2022 | -18.79% |
| Jun 30, 2022 | -15.00% |
| Mar 31, 2022 | -0.59% |
| Dec 31, 2021 | -17.56% |
| Sep 30, 2021 | -6.40% |
| Jun 30, 2021 | -9.21% |
| Mar 31, 2021 | -0.07% |
| Dec 31, 2020 | 8.40% |
| Sep 30, 2020 | 11.32% |
| Jun 30, 2020 | 5.75% |
| Mar 31, 2020 | -3.32% |
| Dec 31, 2019 | 0.15% |
| Sep 30, 2019 | 4.19% |
| Jun 30, 2019 | 1.38% |
| Mar 31, 2019 | -8.35% |
| Dec 31, 2018 | -12.44% |
| Sep 30, 2018 | -8.10% |
| Jun 30, 2018 | -11.52% |
| Mar 31, 2018 | -24.32% |
| Dec 31, 2017 | -8.40% |
| Sep 30, 2017 | -11.81% |
| Jun 30, 2017 | -40.47% |
| Mar 31, 2017 | -38.34% |
| Dec 31, 2016 | -59.11% |
| Sep 30, 2016 | -130.41% |
| Jun 30, 2016 | -207.81% |
| Mar 31, 2016 | -244.68% |
| Dec 31, 2015 | -247.16% |
| Sep 30, 2015 | -270.72% |
| Jun 30, 2015 | -415.80% |
| Mar 31, 2015 | -421.39% |
| Dec 31, 2014 | -605.34% |
| Sep 30, 2014 | -409.35% |